Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Biocartis Group NV (BCART)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.29 0.00    0.00%
31/12 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Belgium
ISIN:  BE0974281132 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.29 - 0.29
Biocartis Group NV 0.29 0.00 0.00%

Biocartis Group NV Company Profile

 
Get an in-depth profile of Biocartis Group NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

526

Equity Type

ORD

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Contact Information

Address Generaal de Wittelaan 11 B
Mechelen, 2800
Belgium
Phone 32 1 563 26 00
Fax -

Top Executives

Name Age Since Title
Michael F. Press - - Member of Scientific Advisory Board
Ann-Christine Sundell 59 2018 Non Executive Independent Director
Jean-Louis Vincent - - Member of Scientific Advisory Board
Eric Van Cutsem - - Member of Scientific Advisory Board
Alberto Bardelli - - Member of Scientific Advisory Board
Pasi Antero Janne - - Member of Scientific Advisory Board
Bert Niesters 65 - Member of Scientific Advisory Board
Luc Gijsens 69 2018 Non-Executive Independent Director
Josep Tabernero - - Member of Scientific Advisory Board
Bryan M. Dechairo 50 2023 Non-Executive Independent Director
Christine D. Kuslich 55 2020 Non Executive Independent Director
Herman Verrelst 49 2017 Independent Chairman of the Board
Geert Maertens - - Chairman of Scientific Advisory Board & Chief Scientific Officer
Christian Reinaudo 69 2018 Independent Director
Anthony Sireci - 2023 Member of Medical Advisory Board
Maria Arcila - 2023 Member of Medical Advisory Board
Bradley Carl Meyer - 2024 Independent Director
David W. Young - 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BCART Comments

Write your thoughts about Biocartis Group NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Roel Munt
CrustyCrabz Nov 13, 2020 11:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
seems a risky one
Kim Maes
Kim Maes Nov 11, 2020 3:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Goeiemorgen, als je wil kopen onder de 5 is het nu de moment....
Kim Maes
Kim Maes Nov 10, 2020 6:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Big stock
Dimitri Tasevski
Dimitri Tasevski Sep 19, 2020 5:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock will go 200% high next week
Mark Swaelen
Mark Swaelen Sep 29, 2019 5:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In what sense does Biocartis differ from Theranos of Elisabeth Holmes which was one big lie ?
Robbe Cobb
Cobb Sep 29, 2019 5:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Theranos never delivered peer reviewed research and wasn't transparent.. . . Biocartis has a lot of information available on their website.. . . I'm sure the Theranos scandal has hurt Biocartis' sales in the short term but I don't see how it will have an effect in the long term.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email